

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/748,720	12/30/2003	Philip Jordan Thomas	UTSD:703USCI	7522	
7590 12/13/2007 Steven L. Highlander FULBRIGHT & JAWORSKI L.L.P.			EXAMINER		
			GUZO, DAVID		
600 Congress A Austin, TX 7870	venue, Suite 2400		ART UNIT	PAPER NUMBER	
	•		1636		
			'		
			MAIL DATE	DELIVERY MODE	
			12/13/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

, , the			•
	<u>.</u>	Application No.	Applicant(s)
		10/748,720	THOMAS ET AL.
	Office Action Summary	Examiner	Art Unit
		David Guzo	1636
Period fo	• •		
VVHI( - Exte after - If NO - Failu Any	CORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES INSTRUMENT OF THE MAILING DATES IN SIX (6) MONTHS from the mailing date of this communication. Of period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing led patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirn vill apply and will expire SIX (6) MONTHS from 1. cause the application to become ABANDONE	N. the mailing date of this communication. D (35 U.S.C. § 133).
Status			
1)⊠	Responsive to communication(s) filed on 10 Ap	oril 2007.	
,	•	action is non-final.	
3)⊠	Since this application is in condition for allowar closed in accordance with the practice under E		
Disposit	ion of Claims		
5)⊠ 6)□ 7)□	Claim(s) <u>44-58</u> is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) <u>44-58</u> is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.	
Applicat	ion Papers		
10)⊠	The specification is objected to by the Examine The drawing(s) filed on <u>30 December 2003</u> is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	re: a) $\boxtimes$ accepted or b) $\square$ object drawing(s) be held in abeyance. See ion is required if the drawing(s) is object.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority (	under 35 U.S.C. § 119		
a)	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority application from the International Bureau  See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachmer	nt(s)		
1) Notice	ce of References Cited (PTO-892)	4) Interview Summary	
2) Notice 3) Information	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Mail Da 5)	atent Application

Continuation of Attachment(s) 6). Other: Notice to Comply with Sequence Rules.

10/748,720 Art Unit: 1636

## **Detailed Action**

This application is in condition for allowance except for the following formal matters:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, the response filed 5/25/05 did not include an amendment specifically directing entry of the paper copy of the Sequence Listing into the specification.

Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Also, it is noted that the oath in the instant application claims priority to provisional application 60/182,283; however, the first page of the specification has not been amended to reflect this. It is unclear if applicants mean to claim priority to the 60/182,283 application. If applicants mean to claim priority to the provisional application, this must be done on the first page of the specification or in an Application Data Sheet (ADS).

Prosecution on the merits is closed in accordance with the practice under *Ex* parte Quayle, 25 USPQ 74, 453 O.G. 213, (Comm'r Pat. 1935).

10/748,720 Art Unit: 1636 Page 3

A shortened statutory period for reply to this action is set to expire TWO

MONTHS from the mailing date of this letter.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, Ph.D., can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo December 3, 2007

PRIMARY EXAMINER

## **Notice to Comply**

Application No. 10/748,720	Applicant(s)  Jordan ET AL.	
Examiner David Guzo	Art Unit 1636	

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
$\boxtimes$	7. Other: Amendment directing entry of the paper copy of the Sequence Listing lacking.
Ар	plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its ry into the application.
⊠ incl	A statement that the content of the paper and computer readable copies are the same and, where applicable, ude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	r questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951

For CRF Submission Help, call (571) 272-2510

PatentIn Software Program Support

Technical Assistance 1-866-217-9197 or 703-305-3028 or 571-272-6845

Patentin Software is Available At www.USPTO.gov

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY